Nasdaq

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Treatment with Annamycin results in statistically significant ...
Nasdaq

Moleculin Biotech Initiates Enrollment in Phase 3 MIRACLE Trial of Annamycin for Relapsed/Refractory AML, Receives EMA Approval for Expanded Study Regions

Moleculin Biotech initiates Phase 3 MIRACLE trial for Annamycin in R/R AML, with EMA approval adding nine European countries. Moleculin Biotech, Inc. has commenced enrollment and dosing in its Phase 3 ...
Morningstar

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107) Provided by GlobeNewswire Jun 5, ...
WJHL-TV

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

HOUSTON, Sept. 23, 2024 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates ...
KRON4 News

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates ...